Protective antitumor immunity induced by tumor cell lysates conjugated with diphtheria toxin and adjuvant epitope in mouse breast tumor models
Authors:
Open Access
- 5 June 2012
- journal article
- Published by Editorial Office of Chinese Journal of Cancer in Chinese Journal of Cancer
- Vol. 31 (6) , 295-304
Abstract
Cancer cell vaccine-based immunotherapy has received increasing interest in many clinical trials involving patients with breast cancer. Combining with appropriate adjuvants can enhance the weak immunogenic properties of tumor cell lysates (TCL). In this study, diphtheria toxin (DT) and two tandem repeats of mycobacterial heat shock protein 70 (mHSP70) fragment 407-426 (M2) were conjugated to TCL with glutaraldehyde, and the constructed cancer cell vaccine was named DT-TCL-M2. Subcutaneous injection of DT-TCL-M2 in mice effectively elicited tumor-specific polyclonal immune responses, including humoral and cellular immune responses. High levels of antibodies against TCL were detected in the serum of immunized mice with ELISA and verified with Western blot analyses. The splenocytes from immunized mice showed potent cytotoxicity on Ehrlich ascites carcinoma cells. Moreover, the protective antitumor immunity induced by DT-TCL-M2 inhibited tumor growth in a mouse breast tumor model. DT-TCL-M2 also attenuated tumor-induced angiogenesis and slowed tumor growth in a mouse intradermal tumor model. These findings demonstrate that TCL conjugated with appropriate adjuvants induced effective antitumor immunity in vivo. Improvements in potency could further make cancer cell vaccines a useful and safe method for preventing cancer recurrence after resection.Keywords
This publication has 42 references indexed in Scilit:
- Comparative effects of carrier proteins on vaccine-induced immune responseVaccine, 2011
- Vaccination With OK-432 Followed by TC-1 Tumor Lysate Leads to Significant Antitumor EffectsReproductive Sciences, 2011
- A novel therapeutic vaccine of GM-CSF/TNFα surface-modified RM-1 cells against the orthotopic prostatic cancerVaccine, 2010
- Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLsVaccine, 2007
- [Killing activity of cytotoxic T lymphocytes stimulated by dendritic cell vaccine loaded with autologous cervical cancer antigen].2006
- Breast cancer vaccines: a clinical reality or fairy tale?Annals of Oncology, 2005
- Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefitsVaccine, 2005
- Identification of Stimulating and Inhibitory Epitopes within the Heat Shock Protein 70 Molecule That Modulate Cytokine Production and Maturation of Dendritic CellsThe Journal of Immunology, 2005
- Novel OK-432-conjugated Tumor Vaccines Induce Tumor-specific Immunity against Murine Tongue CancerJournal of Dental Research, 2003
- Development of therapeutic vaccines by direct modification of cell membranes from surgically removed human tumor tissue with immunostimulatory moleculesVaccine, 2001